FDA Backs Perspective Therapeutics' Novel Neuroendocrine Tumor Treatment Trial Expansion

Rhea-AI Filing Summary

Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.

Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.

The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.

Positive

• FDA approval to open third dosing cohort in Phase 1/2a trial for [212Pb]VMT-α-NET, indicating trial progression and regulatory alignment
• Acceptance of dosimetry sub-study data for presentation at major industry conference (Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting), suggesting positive clinical development progress

Negative

• None.

Insights

Clinical Development Analyst

Perspective Therapeutics advances its lead radiopharmaceutical to third dosing cohort with FDA alignment, while presenting imaging data at major industry conference.

The FDA alignment to proceed to the third dosing cohort represents a significant milestone in Perspective Therapeutics' clinical development program. In Phase 1/2a trials, dose escalation typically proceeds only when safety parameters at lower doses are deemed acceptable, suggesting the treatment has demonstrated a satisfactory safety profile thus far.

The trial focuses on [212Pb]VMT-α-NET for patients with neuroendocrine tumors expressing somatostatin receptor 2 who haven't received prior radiopharmaceutical therapies. This patient selection criteria indicates the company is positioning their therapy potentially as an earlier line of treatment rather than only for previously treated patients.

Simultaneously, the company is conducting a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent, which was presented at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting. Dosimetry studies are crucial in radiopharmaceutical development as they help optimize the therapeutic dose by measuring radiation distribution and absorption in the body.

The updated corporate presentation filed immediately following these developments suggests the company views these advancements as material to their overall strategic positioning and timeline.

For a clinical-stage biopharmaceutical company, these developments represent concrete progress in their clinical program, particularly the advancement to higher dosing levels with regulatory alignment. The presentation at a major scientific conference also provides visibility among key opinion leaders in nuclear medicine.

0000728387false00007283872025-06-212025-06-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2025

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 21, 2025, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing that alignment was reached with the U.S. Food and Drug Administration to open the third dosing cohort of its ongoing Phase 1/2a clinical trial for [212Pb]VMT‑α‑NET in patients with unresectable or metastatic somatostatin receptor 2‑positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Additionally, on June 21, 2025, the Company issued a press release and posted to its website a presentation regarding a dosimetry sub-study using [202Pb]VMT‑α‑NET as an imaging agent in the Company’s ongoing Phase 1/2a clinical trial of [212Pb]VMT‑α‑NET that was accepted for presentation at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting, which is taking place from June 21-24, 2025 in New Orleans, Louisiana. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. A copy of the presentation is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

On June 23, 2025, the Company updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.4 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release #1 issued by Perspective Therapeutics, Inc., dated June 21, 2025.
99.2		Press release #2 issued by Perspective Therapeutics, Inc., dated June 21, 2025.
99.3		Presentation regarding data presented at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting.
99.4		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	June 23, 2025	By:	/s/ Johan (Thijs) Spoor
			Johan (Thijs) Spoor Chief Executive Officer

FAQ

What did CATX announce in their June 21, 2025 8-K filing?

CATX announced two key developments: 1) FDA alignment to open the third dosing cohort of their Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with neuroendocrine tumors, and 2) acceptance of a dosimetry sub-study presentation using [202Pb]VMT-α-NET at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting.

What type of patients are eligible for CATX's Phase 1/2a clinical trial?

The clinical trial is for patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies.

Where and when will CATX present their dosimetry sub-study results?

CATX will present their dosimetry sub-study results at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting, taking place from June 21-24, 2025 in New Orleans, Louisiana.

What exhibits were included in CATX's June 2025 8-K filing?

The filing included 5 exhibits: two press releases dated June 21, 2025, a presentation of data for the SNMMI 2025 Annual Meeting, an updated corporate presentation, and a Cover Page Interactive Data File (embedded within the Inline XBRL document).

Who is the current CEO of CATX as of June 2025?

Johan (Thijs) Spoor is the Chief Executive Officer of Perspective Therapeutics, Inc. (CATX), as evidenced by his signature on the 8-K filing dated June 23, 2025.